Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancerJuan Zhou, Chunxia Su, Lihong Wu et al.|BMC Medicine|2022Cited by 21
Additional file 1 of Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancerJuan Zhou, Chunxia Su, Minwei Bao et al.|Open MIND|2022Cited by 0